For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Triptorelin - Transgender Health - Children & Young People
PAD Profile : Triptorelin - Transgender Health - Children & Young People
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for puberty supressing hormones in children and young people under the following circumstances:
i. ONLY for current NHS and private patients at least until next reviewed by the service lead clinician. Always ensure that appropriate shared care protocols are in place before continuing prescribing. Private patients should be advised of the new NHS policy and recommendation made to return to the private provider for consideration of stopping.
ii. DO NOT initiate in any new patients
In December 2023, a guide to support primary care prescribing for people who access gender identity services was agreed by the APC.
The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.